Outcome | Methacholine PC20 (mg/ml) | ||
Group A n= 82 | Group B n= 60 | Group C n=66 | |
≤0.5 | >0.5–2 | >2–8 | |
FEV1% | 86.5 (82.9–90.1)* | 90.4 (87.4–93.5) | 95.0 (91.4–98.7)* |
FENO | 28.1 (23.4–33.8)* | 30.6 (24.9–37.6) | 39.3 (32.8–47.0)* |
No. +ve Skin Pricks | 3 (2-5) | 3 (2-5) | 3 (1-4) |
% on ICS | 53% | 51% | 39% |
Median BDP dose (ug) | 400 | 400 | 400 |
Outcome | Exhaled Nitric Oxide (FENO) (ppb) | ||
Group D n=79 | Group E n=72 | Group F n=57 | |
≤25 | >25-50 | >50 | |
FEV1% | 89.9 (86.7–93.1) | 91.5 (87.8–95.3) | 88.9 (85.0–92.9) |
Methacholine PC20 | 0.99 (0.67–1.47)* | 0.59 (0.39–0.89) | 0.41 (0.26–0.63)* |
No. +ve skin pricks | 3 (2–4) | 3 (2–4) | 3 (2–5) |
% on ICS | 41% | 44% | 33% |
Median BDP dose (μg) | 400 | 400 | 400 |
↵* Significant difference between groups A versus C or between D versus F p<0.05.